[go: up one dir, main page]

WO2006136461A3 - Procede de fabrication de vaccins viraux dans des lignees de cellules souches embryonnaires aviaires derivees en suspension - Google Patents

Procede de fabrication de vaccins viraux dans des lignees de cellules souches embryonnaires aviaires derivees en suspension Download PDF

Info

Publication number
WO2006136461A3
WO2006136461A3 PCT/EP2006/006531 EP2006006531W WO2006136461A3 WO 2006136461 A3 WO2006136461 A3 WO 2006136461A3 EP 2006006531 W EP2006006531 W EP 2006006531W WO 2006136461 A3 WO2006136461 A3 WO 2006136461A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor modulators
progesterone receptor
therapy
prophylaxis
steroidal progesterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/006531
Other languages
English (en)
Other versions
WO2006136461A2 (fr
Inventor
Alexander Hillisch
Ulrich Bothe
Guenter Kaufmann
Lothar Sobek
Ulrike Fuhrmann
Peter Droescher
Norbert Schmees
Wolfgang Schwede
Carsten Moeller
Anja Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP06762404A priority Critical patent/EP1902049A2/fr
Priority to BRPI0611903-4A priority patent/BRPI0611903A2/pt
Priority to CA002611897A priority patent/CA2611897A1/fr
Priority to EA200702524A priority patent/EA200702524A1/ru
Priority to AU2006261048A priority patent/AU2006261048A1/en
Priority to MX2008000072A priority patent/MX2008000072A/es
Priority to JP2008517444A priority patent/JP2008543910A/ja
Application filed by Schering AG filed Critical Schering AG
Publication of WO2006136461A2 publication Critical patent/WO2006136461A2/fr
Publication of WO2006136461A3 publication Critical patent/WO2006136461A3/fr
Priority to IL188021A priority patent/IL188021A0/en
Anticipated expiration legal-status Critical
Priority to NO20080440A priority patent/NO20080440L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne le développement et la fabrication de vaccins viraux. Plus précisément, l'invention concerne le domaine de la production industrielle de vecteurs et de vaccins viraux, plus précisément encore, l'utilisation de cellules souches embryonnaires aviaires, de préférence, la lignée de cellules Ebx dérivées de cellules souches embryonnaires de poulets, aux fins de production de vecteurs et de vaccins viraux. Le développement et la fabrication de vaccins viraux selon l'invention sont spécialement utiles dans la production industrielle de vaccins viraux permettant de prévenir une infection virale chez les êtres humaines et les animaux.
PCT/EP2006/006531 2005-06-24 2006-06-22 Procede de fabrication de vaccins viraux dans des lignees de cellules souches embryonnaires aviaires derivees en suspension Ceased WO2006136461A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0611903-4A BRPI0611903A2 (pt) 2005-06-24 2006-06-22 moduladores de receptor de progesterona não-esteroidal
CA002611897A CA2611897A1 (fr) 2005-06-24 2006-06-22 Procede de fabrication de vaccins viraux dans des lignees de cellules souches embryonnaires aviaires derivees en suspension
EA200702524A EA200702524A1 (ru) 2005-06-24 2006-06-22 Нестероидные модуляторы рецептора прогестерона
AU2006261048A AU2006261048A1 (en) 2005-06-24 2006-06-22 Non-steroidal progesterone receptor modulators
MX2008000072A MX2008000072A (es) 2005-06-24 2006-06-22 Moduladores no esteroides de receptor de progesterona.
EP06762404A EP1902049A2 (fr) 2005-06-24 2006-06-22 Modulateurs non steroidiens du recepteur de la progesterone
JP2008517444A JP2008543910A (ja) 2005-06-24 2006-06-22 非ステロイド性プロゲステロン受容体モジュレーター
IL188021A IL188021A0 (en) 2005-06-24 2007-12-10 Non-steroidal progesterone receptor modulators
NO20080440A NO20080440L (no) 2005-06-24 2008-01-23 Ikke-steroide progesteronreseptormodulatorer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005030292.0 2005-06-24
DE102005030292A DE102005030292A1 (de) 2005-06-24 2005-06-24 Nichtsteroidale Progesteronrezeptor-Modulatoren

Publications (2)

Publication Number Publication Date
WO2006136461A2 WO2006136461A2 (fr) 2006-12-28
WO2006136461A3 true WO2006136461A3 (fr) 2007-03-15

Family

ID=37199176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006531 Ceased WO2006136461A2 (fr) 2005-06-24 2006-06-22 Procede de fabrication de vaccins viraux dans des lignees de cellules souches embryonnaires aviaires derivees en suspension

Country Status (22)

Country Link
EP (1) EP1902049A2 (fr)
JP (1) JP2008543910A (fr)
KR (1) KR20080030622A (fr)
CN (1) CN101248066A (fr)
AR (1) AR054519A1 (fr)
AU (1) AU2006261048A1 (fr)
BR (1) BRPI0611903A2 (fr)
CA (1) CA2611897A1 (fr)
CR (1) CR9598A (fr)
DE (1) DE102005030292A1 (fr)
DO (1) DOP2006000148A (fr)
EA (1) EA200702524A1 (fr)
EC (1) ECSP078044A (fr)
GT (1) GT200600271A (fr)
IL (1) IL188021A0 (fr)
MX (1) MX2008000072A (fr)
NO (1) NO20080440L (fr)
PE (1) PE20070125A1 (fr)
TW (1) TW200740778A (fr)
UY (1) UY29624A1 (fr)
WO (1) WO2006136461A2 (fr)
ZA (1) ZA200800690B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
DE102007032800A1 (de) * 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
JP2011519916A (ja) * 2008-07-02 2011-07-14 ファーマコステック カンパニー リミテッド アミド誘導体の製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344776A1 (fr) * 2002-03-11 2003-09-17 Schering Aktiengesellschaft Dérivés de la 5- 2-hydroxy-3-[1-(3-trifluorométhylphényl)-cyclopropyl]-propionylamino -phtalide et de la 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one avec une activité modulante du recepteur de la progesterone pour l'utilisation dans la contraception , la therapie du remplacement hormonell et le traitement des troubles gynécologiques
WO2005003098A1 (fr) * 2003-07-01 2005-01-13 Schering Aktiengesellschaft Derives de pentanol substitues par un heterocycle, procede de production de ces composes et leur utilisation comme agents anti-inflammatoires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344776A1 (fr) * 2002-03-11 2003-09-17 Schering Aktiengesellschaft Dérivés de la 5- 2-hydroxy-3-[1-(3-trifluorométhylphényl)-cyclopropyl]-propionylamino -phtalide et de la 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one avec une activité modulante du recepteur de la progesterone pour l'utilisation dans la contraception , la therapie du remplacement hormonell et le traitement des troubles gynécologiques
WO2005003098A1 (fr) * 2003-07-01 2005-01-13 Schering Aktiengesellschaft Derives de pentanol substitues par un heterocycle, procede de production de ces composes et leur utilisation comme agents anti-inflammatoires

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM., vol. 11, no. 18, 2003, pages 4133 - 4142 *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002406053, Database accession no. 1735553, 1964392, 2329868, 3529064 (RID). *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002406062, Database accession no. 2214047 (RID) *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002406063, Database accession no. 4338477 (RID) *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002406064, Database accession no. 9573837 (RID) *
DATABASE BEILSTEIN Beilstein Institut zur Förderung der Wissenschaften, Frankfurt/Main, DE; XP002406065, Database accession no. 4064999 (RID) *
J. AM. CHEM. SOC., vol. 116, no. 24, 1994, pages 10955 - 10965 *
J. CHEM. SOC. CHEM. COMMUN., vol. 4, 1990, pages 294 - 296 *
J. HETEROCYCL. CHEM., vol. 32, no. 4, 1995, pages 1133 - 1140 *
J. PHARM.SCI., vol. 82, no. 6, 1993, pages 605 - 609 *

Also Published As

Publication number Publication date
AR054519A1 (es) 2007-06-27
DE102005030292A1 (de) 2007-01-11
CN101248066A (zh) 2008-08-20
ECSP078044A (es) 2008-01-23
CA2611897A1 (fr) 2006-12-28
ZA200800690B (en) 2009-09-30
EA200702524A1 (ru) 2008-06-30
NO20080440L (no) 2008-03-25
TW200740778A (en) 2007-11-01
JP2008543910A (ja) 2008-12-04
GT200600271A (es) 2007-02-05
EP1902049A2 (fr) 2008-03-26
IL188021A0 (en) 2008-03-20
PE20070125A1 (es) 2007-02-14
AU2006261048A1 (en) 2006-12-28
CR9598A (es) 2008-04-09
MX2008000072A (es) 2008-03-24
WO2006136461A2 (fr) 2006-12-28
UY29624A1 (es) 2007-01-31
DOP2006000148A (es) 2007-07-15
BRPI0611903A2 (pt) 2010-10-05
KR20080030622A (ko) 2008-04-04

Similar Documents

Publication Publication Date Title
WO2011009530A3 (fr) Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-acyloxyalcénylphényle, procédés de préparation et utilisation pour le traitement de maladies
WO2011009531A3 (fr) Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies
WO2011009529A3 (fr) Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-méthylénoxyalcénylaryle, procédés de préparation et utilisation pour le traitement de maladies
WO2011098437A3 (fr) Antagonistes du récepteur de la progestérone
MX2009009581A (es) Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.
UA98138C2 (ru) Производные бензамида как модуляторы фолликулостимулирующего гормона
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
TN2012000618A1 (en) 6,7-dihydro-5h-benzo[7]annulene derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and the use thereof for production of medicaments
WO2009105214A3 (fr) Modulateurs sélectifs du récepteur de l'androgène
WO2004000801A3 (fr) Utilisation de derives de cyclothiocarbamate pour le traitement de pathologies d'origine hormonale
WO2004000225A3 (fr) Utilisation de derives de thio-oxindole dans le traitement d'etats pathologiques lies aux hormones
WO2007113202A8 (fr) Dérivés de pipérazine utilisés comme agonistes du récepteur du sécrétagogue de l'hormone de croissance (shc)
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
WO2007103867A3 (fr) Préparations sous forme de comprimé et procédés associés
WO2008113851A3 (fr) Nouveaux rétrostéroïdes modifiés par c11 en tant que composés modulateurs du récepteur de la progestérone
WO2007016385A3 (fr) Utilisation des modulateurs du recepteur de la progesterone
ECSP078043A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
WO2006136461A3 (fr) Procede de fabrication de vaccins viraux dans des lignees de cellules souches embryonnaires aviaires derivees en suspension
WO2008152094A3 (fr) Acétamides substitués en tant que modulateurs du récepteur ep2
WO2008077647A3 (fr) Modulateurs de récepteurs de progestérone non-stéroïdiens
UY29625A1 (es) Uso de moduladores no esteroides de receptores de progesterona
WO2009043577A3 (fr) 19-norprogestérone utilisée en tant que contraceptif
WO2009007454A3 (fr) Estratriènes à substitution 8-bêta servant d'œstrogènes sélectivement actifs
UY30815A1 (es) Moduladores no esteroidales del receptor de progesterona

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 188021

Country of ref document: IL

Ref document number: 2006261048

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006762404

Country of ref document: EP

Ref document number: 2611897

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: CR2007-009598

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200702524

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12007502912

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008517444

Country of ref document: JP

Ref document number: 564741

Country of ref document: NZ

Ref document number: 07135474

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 9967/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/000072

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2006261048

Country of ref document: AU

Date of ref document: 20060622

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006261048

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087001793

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200680030870.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006762404

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0611903

Country of ref document: BR

Kind code of ref document: A2